ProSensa B.V. Awarded EUR 6 Million EU FP7 Research Grant

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Leiden, The Netherlands, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has been awarded a prestigious Framework Programme 7 (FP7) research grant from the European Union to support the ongoing clinical study of the Company's third novel development candidate, PRO045, for the treatment of Duchenne muscular dystrophy (DMD).

Help employers find you! Check out all the jobs and post your resume.

Back to news